Stockscreener 앱 받기
24.27
0.74%
-0.18
시간 외 거래:
24.27
전일 마감가:
$24.45
열려 있는:
$24.53
하루 거래량:
1.12M
Relative Volume:
0.91
시가총액:
$2.98B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
20.57
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-3.77%
1개월 성능:
+6.82%
6개월 성능:
+22.21%
1년 성능:
+6.63%
1일 변동 폭
$24.03
$24.60
1주일 범위
$23.73
$25.40
52주 변동 폭
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.27 | 3.01B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup - Chartmill
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years - Yahoo Finance
What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - Mfd.ru
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Federated Hermes Inc. - MarketBeat
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Growth Strength And Positive Analyst Sentiment - Sahm
Aug Reactions: Is EDHL subject to activist investor interest2025 Volume Leaders & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)? - Sahm
Ruffer LLP Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Screens as an Affordable Growth Stock - Chartmill
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Exploring A 45% Upside Potential - DirectorsTalk Interviews
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Y Intercept Hong Kong Ltd - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - The Motley Fool
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Fresh Rare Disease Momentum And Earnings Outperformance - Sahm
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory - Insider Monkey
Campbell & CO Investment Adviser LLC Has $1.93 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
How Investors May Respond To Catalyst Pharmaceuticals (CPRX) Rare-Disease Strength And Potential Technical Breakout - Sahm
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock” - Insider Monkey
First Week of September 18th Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
SG Americas Securities LLC Raises Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup - Chartmill
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - sharewise.com
Short Squeeze: What is the next catalyst for Actinium Pharmaceuticals IncProfit Target & Technical Confirmation Trade Alerts - baoquankhu1.vn
Bank Watch: Is Catalyst Pharmaceuticals Inc. stock influenced by commodity pricesJuly 2025 Review & Weekly Momentum Picks - baoquankhu1.vn
Catalyst Pharmaceuticals (CPRX) Stock Analysis: A 50% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Catalyst Pharmaceuticals, Inc. Presents at JP Morgan Healthcare Conference - TradingView
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Forbes 2026 Small Cap Recognition - Sahm
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today - MSN
Will Catalyst Pharmaceuticals Inc. stock see insider buyingQuarterly Trade Summary & Daily Stock Trend Reports - ulpravda.ru
How Catalyst Pharmaceuticals Inc. stock benefits from tech adoption2025 Trading Recap & Fast Momentum Stock Entry Tips - ulpravda.ru
Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? - Yahoo Finance
How Forbes’ Small-Cap Accolade Will Impact Catalyst Pharmaceuticals (CPRX) Investors - Sahm
Will Catalyst Pharmaceuticals Inc. stock benefit from green energy trendsEntry Point & Consistent Profit Trading Strategies - Улправда
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - AOL.com
How Catalyst Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Exit Report & Verified Chart Pattern Trade Signals - ulpravda.ru
Funds from operations of Catalyst Pharmaceuticals, Inc. – FWB:CN2 - TradingView — Track All Markets
Is Catalyst Pharmaceuticals Inc. stock a buy before product launchesJuly 2025 Market Mood & Real-Time Market Trend Scan - ulpravda.ru
Will Catalyst Pharmaceuticals Inc. stock maintain dividend yield2025 Geopolitical Influence & Free Community Consensus Stock Picks - Улправда
Santhera Seals APAC Pact For Agamree - Citeline News & Insights
Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now? - Yahoo Finance
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies - The Manila Times
Catalyst Pharmaceuticals Receives Prestigious Ranking on - GlobeNewswire
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Cross Above 200-Day Moving AverageHere's Why - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.16%
자본화:
|
볼륨(24시간):